التفاصيل البيبلوغرافية
| العنوان: |
Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies. |
| المؤلفون: |
Jacob, Aasems1 (AUTHOR) aasems.jacob@pikevillehospital.org, Raj, Rishi2 (AUTHOR) Rishi.Raj@pikevillehospital.org, Allison, Derek B.3,4,5 (AUTHOR) Derek.Allison@uky.edu, Myint, Zin W.3,6 (AUTHOR) zin.myint@uky.edu |
| المصدر: |
Cancers. Nov2021, Vol. 13 Issue 21, p5417. 1p. |
| مصطلحات موضوعية: |
*THERAPEUTIC use of antineoplastic agents, *CYTOKINES, *GENETIC mutation, *NEUROENDOCRINE system, *DNA, *ONCOGENES, *PHOSPHOTRANSFERASES, *METASTASIS, *SIGNAL peptides, *CELLULAR signal transduction, *GENE expression, *STEM cells, *TRANSFERASES, *ANDROGEN receptors, *TUMOR markers, *MITOGEN-activated protein kinases, *PROSTATE tumors, *DRUG resistance in cancer cells |
| مستخلص: |
Simple Summary: Early-stage and castration-sensitive prostate cancer (PCa) growth is solely mediated by androgen signaling pathways. AR signaling inhibitors (ARSIs) have significantly improved clinical outcomes among men with PCa. In the metastatic castration-resistant PCa, there is presence of both androgen-dependent and androgen-independent cells driving the tumor growth. Despite the use of ARSIs, disease progression ultimately occurs in all patients with PCa and is due to genetic alterations in ARs, resulting in the outgrowth of androgen-independent cells. The possible mechanisms include development of AR splice variants of which AR-V7 is more common, AR point mutations, and AR overexpression. In addition, restoration of downstream signaling through alternate pathways can also lead to androgen-independent growth of PCa. Therapeutic strategies to overcome these resistance mechanisms and establish predictive biomarkers are still in clinical trials. This review article details the current evidence on clinically relevant driver mechanisms, relevant biomarkers, and treatment modalities to overcome resistance. Understanding of the molecular mechanisms of prostate cancer has led to development of therapeutic strategies targeting androgen receptor (AR). These androgen-receptor signaling inhibitors (ARSI) include androgen synthesis inhibitor-abiraterone and androgen receptor antagonists-enzalutamide, apalutamide, and darolutamide. Although these medications provide significant improvement in survival among men with prostate cancer, drug resistance develops in nearly all patients with time. This could be through androgen-dependent or androgen-independent mechanisms. Even weaker signals and non-canonical steroid ligands can activate AR in the presence of truncated AR-splice variants, AR overexpression, or activating mutations in AR. AR splice variant, AR-V7 is the most studied among these and is not targeted by available ARSIs. Non-androgen receptor dependent resistance mechanisms are mediated by activation of an alternative signaling pathway when AR is inhibited. DNA repair pathway, PI3K/AKT/mTOR pathway, BRAF-MAPK and Wnt signaling pathway and activation by glucocorticoid receptors can restore downstream signaling in prostate cancer by alternative proteins. Multiple clinical trials are underway exploring therapeutic strategies to overcome these resistance mechanisms. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder